På tilbagetrækningstidspunktet var det derfor CHMP' s opfattelse, at fordelene ikke var tilfredsstillende godtgjort og ikke opvejede de påviste risici.
Therefore, at the time of the withdrawal, the CHMP’ s view was that the benefit had not been sufficiently demonstrated and did not outweigh the identified risks.